These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 23113478

  • 1. A shift on "pay for delay"--reopening doors for pharmaceutical competition?
    Hemphill Kraus EJ.
    N Engl J Med; 2012 Nov 01; 367(18):1681-3. PubMed ID: 23113478
    [No Abstract] [Full Text] [Related]

  • 2. The ongoing regulation of generic drugs.
    Frank RG.
    N Engl J Med; 2007 Nov 15; 357(20):1993-6. PubMed ID: 18003956
    [No Abstract] [Full Text] [Related]

  • 3. A generic problem.
    Hanauer SB.
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec 15; 3(12):649. PubMed ID: 17130869
    [No Abstract] [Full Text] [Related]

  • 4. Delaying generic competition--corporate payoffs and the future of Plavix.
    Shuchman M.
    N Engl J Med; 2006 Sep 28; 355(13):1297-300. PubMed ID: 17005945
    [No Abstract] [Full Text] [Related]

  • 5. The "reverse payment paradox": an overview of the legality of reverse exclusionary payments in the pharmaceutical industry.
    Brockmeier MS.
    Health Care Law Mon; 2010 Mar 28; 2010(3):2-10. PubMed ID: 20329564
    [No Abstract] [Full Text] [Related]

  • 6. The Eleventh Circuit holds that agreements in which pharmaceutical companies pay generic companies not to compete may be valid.
    Garrigues A.
    J Law Med Ethics; 2004 Mar 28; 32(1):181-4. PubMed ID: 15152443
    [No Abstract] [Full Text] [Related]

  • 7. Pharmaceutical patent settlements: the antitrust risks.
    Balto DA.
    Food Drug Law J; 2000 Mar 28; 55(3):321-41. PubMed ID: 11824464
    [No Abstract] [Full Text] [Related]

  • 8. Branded drug reformulation: the next brand vs. generic antitrust battleground.
    Amoresano GV.
    Food Drug Law J; 2007 Mar 28; 62(1):249-56. PubMed ID: 17444032
    [No Abstract] [Full Text] [Related]

  • 9. Settlements between brand and generic pharmaceutical companies: a reasonable antitrust analysis of reverse payments.
    Yvon AM.
    Fordham Law Rev; 2006 Dec 28; 75(3):1883-912. PubMed ID: 17312596
    [No Abstract] [Full Text] [Related]

  • 10. Revitalizing the patent system to incentivize pharmaceutical innovation: the potential of claims with means-plus-function clauses.
    Tang WL.
    Duke Law J; 2013 Feb 28; 62(5):1069-108. PubMed ID: 25330553
    [Abstract] [Full Text] [Related]

  • 11. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
    Wang Z.
    Cornell Law Rev; 2014 Jul 28; 99(5):1227-58. PubMed ID: 25112001
    [No Abstract] [Full Text] [Related]

  • 12. A brief history of generic substitution in the USA.
    Sullivan CG.
    Pharm Pat Anal; 2012 Mar 28; 1(1):9-11. PubMed ID: 24236706
    [No Abstract] [Full Text] [Related]

  • 13. Are reverse payments and pay-for-delay settlements business as usual or an anticompetitive practice?
    Shah S, Silva MA, Malloy MJ.
    Nat Biotechnol; 2016 Jul 12; 34(7):716-9. PubMed ID: 27404880
    [No Abstract] [Full Text] [Related]

  • 14. Supreme Court to decide whether payments by patent holders to delay production of generics are anticompetitive.
    Roehr B.
    BMJ; 2012 Dec 12; 345():e8464. PubMed ID: 23236054
    [No Abstract] [Full Text] [Related]

  • 15. Understanding the Rewards of Successful Drug Development - Thinking Inside the Box.
    Khullar D, Ohn JA, Trusheim M, Bach PB.
    N Engl J Med; 2020 Jan 30; 382(5):473-480. PubMed ID: 31995697
    [No Abstract] [Full Text] [Related]

  • 16. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984.
    Lewis RA.
    J Contemp Health Law Policy; 1992 Jan 30; 8():361-78. PubMed ID: 10118987
    [No Abstract] [Full Text] [Related]

  • 17. The balance between innovation and competition: the Hatch-Waxman Act, the 2003 Amendments, and beyond.
    Kelly C.
    Food Drug Law J; 2011 Jan 30; 66(3):417-78, iii. PubMed ID: 24505856
    [Abstract] [Full Text] [Related]

  • 18. Generics battle brand names over mortality of drug patents.
    Betz R.
    J Healthc Resour Manag; 1995 Jul 30; 13(7):35-7. PubMed ID: 10144008
    [No Abstract] [Full Text] [Related]

  • 19. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
    Apel BT.
    Mich Law Rev; 2015 Jul 30; 114(1):107-36. PubMed ID: 26394458
    [Abstract] [Full Text] [Related]

  • 20. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
    Soehnge H.
    Food Drug Law J; 2003 Jul 30; 58(1):51-80. PubMed ID: 12739584
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.